Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
Raffaele Nuzzi,1 Giada Geronazzo,1,2 Federico Tridico,1 Alessia Nuzzi,3 Paolo Caselgrandi,1 Antonio Giulio Piga4 1Eye Clinic Section, Department of Surgical Sciences, University of Turin, Turin, Italy; 2Regional Reference Centre for Diagnosis and Cure of Hemoglobinopathies, S. Luigi Gonzaga Universi...
Saved in:
Main Authors: | Nuzzi R, Geronazzo G, Tridico F, Nuzzi A, Caselgrandi P, Piga AG |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/55e38c48e15346089a76b4635cefb219 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients
by: Noppawan Phumala Morales, et al.
Published: (2022) -
An overview of complications associated with deferoxamine therapy in thalassemia
by: Bijan Keikhaei, et al.
Published: (2021) -
Biofortification of cowpea beans with iron: iron´s influence on mineral content and yield
by: Márquez-Quiroz,C, et al.
Published: (2015) -
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
by: Parisi S, et al.
Published: (2021) -
Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers
by: Martin Hruby, et al.
Published: (2021)